Heart failure - implications of the true size of the problem

Journal of Internal Medicine

Volumn 239, Issue 4, 1996, Pages 309-315

  Dargie, H J ^a,c   McMurray, J J V ^b   McDonagh, T A ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ACE inhibitors; Heart failure; Incidence; Prevalence

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE; CONFERENCE PAPER; DRUG EFFICACY; GENDER; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MORTALITY; PREVALENCE; PRIORITY JOURNAL;

EID: 0029921779     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.461800000.x     Document Type: Conference Paper

References (30)

1. Poole-Wilson PA. Heart failure. Med Int 1985; 2: 866-71.
2. Eriksson H, Svardsudd K, Larsson B, Ohlson LO, Tibblin G, Wellin L, Wilhelmsen L. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989; 10: 647-56.
3. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-6.
4. Gibson TC, White KL, Klainer LM. The prevalence of congestive heart failure in two rural communities. J Chronic Dis 1966; 19: 141-52.
5. Parameshwar J, Shackell MM, Richardson A, Poole-Wilson PA, Sutton GC. Prevalence of heart failure in three general practices in north west London. Br J Gen Prac (in press).
6. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med 1971; 285: 781-87.
7. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992; 13: 588-93.
8. Parameshwar J, Poole-Wilson PA, Sutton GC. Heart failure in a district general hospital. J R Coll Physicians Lond 1992; 26: 139-42.
9. Sutton GC. Epidemiologic aspects of heart failure. Am Heart J 1990; 120: 1539-40.
10. McMurray J, Dargie HJ. Trends in hospitalisation for chronic heart failure in the United Kingdom. Eur Heart J 1992; 12 (Suppl.): 350.
11. Sussex BA, Arnold JMO, Parker JO, McEwan P, Rouleau JL, St John Sutton M, et al. Independent and interactive prognostic information of neurohormones and echocardiogram in high risk post-MI patients (Abstract). J Am Coll Cardiol 1992; 19: 205A.
12. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)-rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990; 66: 315-22.
13. Bangdiwala SI, Weiner DH, Bourassa MG, Grioesinger, II, GC, Ghali JK, Yusuf S (for the SOLVD Investigators). Studies of left ventricular dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol 1992; 70: 347-53.
14. McMurray J, McDonagh T, Morrison CE, Dargie HJ. The growing problem of heart failure in Scottish hospitals. Br Heart J 1993; 69 (Suppl.): 73.
15. McMurray J, Hart W. The economic impact of heart failure on the UK National Health Service. Eur Heart J 1993; 14 (Suppl.): 133.
16. Stewart AL, Greenfeld S, Hays RD, Wells K, Rogers WH, Berry SD et al. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989; 262: 907-13.
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
19. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
20. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8 (Suppl. F): 23-6.
21. Cohn JN, Johnson MS and Veterans Administration Cooperative Study Group. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation 1990; 81 (Suppl. III); 111-48-53.
22. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979; 44: 53-9.
23. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA 1988; 260: 2088-93.
24. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J 1993; 307: 349-53.
25. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-21.
26. Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Quart J Med 1993; 86: 17-23.
27. Moye LA, Pfeffer MA, Braunwald E. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol 1991; 68: 70D-79D.
28. Greene HL, Richardson DW, Hallstrom AP et al. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 393-8.
29. McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988; 60: 117-24.
30. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.